VISUDYNE: payments to doctors
Payments that named VISUDYNE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6M
- Providers
- 800
- Transactions
- 1,653
- Average per transaction
- $3,659
The per-transaction average — $3,659 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 800 providers the average total is $7,560, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | $3,277,416 | 54.2% |
| Bausch & Lomb Americas Inc. | $2,770,836 | 45.8% |
| Solta Medical, A Division Of Bausch Health US, LLC | $125 | 0.0% |